ADPT Kronos AI forecast
A 30-trading-day price forecast for Adaptive Biotechnologies Corporation (ADPT) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Adaptive Biotechnologies Corporation at $19.72 on 2026-12-08, −28.7% from the last close of $27.66 on 2026-10-27. Eight out of ten sampled paths end between $17.56 and $23.08, and 0 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of ADPT
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $27.56 | $26.53 | $28.16 |
| 2026-11-10 | $26.31 | $25.49 | $28.79 |
| 2026-11-17 | $24.70 | $23.09 | $27.85 |
| 2026-11-24 | $23.32 | $21.56 | $24.87 |
| 2026-12-01 | $22.23 | $20.35 | $24.27 |
| 2026-12-08 | $19.72 | $17.56 | $23.08 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for ADPT?
- Kronos AI's median forecast for ADPT is $19.72 in 30 trading days, −28.7% from the last close, with a 10–90% range of $17.56 to $23.08.
- Is the ADPT Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- AMGN — Amgen Inc.
- GILD — Gilead Sciences Inc.
- MRNA — Moderna Inc.
- ARGX — argenx SE American Depositary Shares
- RVMD — Revolution Medicines Inc.
- BIIB — Biogen Inc.